6 Moreover, no difference in mortality was seen between
|
|
- Lionel Francis
- 5 years ago
- Views:
Transcription
1 Coronary Revascularization (Surgical or Percutaneous) Decreases Mortality After the First Year in Diabetic Subjects but not in Nondiabetic Subjects With Multivessel Disease An Analysis From the Medicine, Angioplasty, or Surgery Study (MASS II) Paulo R. Soares, MD, PhD; Whady A. Hueb, MD, PhD; Pedro A. Lemos, MD, PhD; Neuza Lopes, MD, PhD; Eulógio E. Martinez, MD, PhD; Luis A.M. Cesar, MD, PhD; Sergio A. Oliveira, MD, PhD; Jose A.F. Ramires, MD, PhD Background It is currently unknown whether revascularization procedures are associated with an improvement in mortality among diabetic subjects, as compared with a more conservative medical treatment. Methods and Results In MASS II, a total of 611 patients with stable multivessel coronary disease were randomly assigned to medical treatment, surgery, or angioplasty. From these, 190 patients had diabetes (medical, 75 patients; angioplasty, 56 patients; surgery, 59 patients) and comprised the present study population. Mortality rates were analyzed for the entire 5 years of follow-up. Separate analyzes were also performed for mortality at 2 time intervals: during the first year and after the first year of follow-up. We calculated the probability of death conditional on surviving to the start of the interval analyzed. The cumulative 5-year mortality as well as the mortality during the first year of follow-up was not significantly different among treatment groups, both for diabetic and for nondiabetic subjects. Also, during years 2 to 5, the mortality of the 3 treatment groups was not different for nondiabetic subjects. Among diabetic subjects, however, patients randomized to angioplasty or surgery had a significantly lower mortality between years 2 and 5 than those allocated to medical treatment (P 0.039). Conclusion Surgery, angioplasty, and medical treatment appear to be associated with similar mortality rates for non-diabetic subjects. For diabetic subjects, however, coronary revascularization (percutaneous or surgical) significantly decreased the risk of death after the first year and up to 5 years, compared with medical treatment alone. (Circulation. 2006;114[suppl I]:I-420 I-424.) Key Words: angioplasty coronary disease diabetes mellitus revascularization surgery Previous studies have shown that the presence of diabetes significantly decreases the adjusted long-term survival even after coronary revascularization either with percutaneous coronary intervention or with bypass surgery. 1 4 When comparing both invasive treatments for patients with multivessel disease, investigators from the Bypass Angioplasty Revascularization Investigation (BARI) study demonstrated that diabetic subjects treated with balloon angioplasty were at increased risk for death in comparison with patients undergoing surgical revascularization. 5 However, the effect of diabetes on the outcomes after invasive treatment still remain controversial. In BARI, the difference in long-term mortality between the study groups was mostly explained by the larger degree of completeness of revascularization in the surgical arm, compared with patients randomized to balloon angioplasty. 6 Moreover, no difference in mortality was seen between coronary surgery and angioplasty in more recent trials using coronary stenting instead of plain balloon dilatation. 7 Currently, scarce information is available on the outcomes of multivessel patients maintained on medical therapy. Medical treatment has improved in the past years with the widespread use of aspirin, beta-blockers, statins, and angiotensin-converting enzyme inhibitors. Most of the recent randomized trials on coronary artery disease did not include a conservative treatment arm. The Medicine, Angioplasty, or Surgery Study (MASS II) has previously compared the outcomes of patients with stable multivessel coronary disease randomized to surgery, angioplasty, or medical treatment, with no evidence of 1-year mortality difference for the overall population. 8 However, to the best of our knowledge, no From Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil. Presented at the American Heart Association Scientific Sessions, Dallas, Tex, November 13 16, Correspondence to Whady Hueb, Heart Institute (InCor), University of Sao Paulo Medical School, Av. Dr. Enéas de Carvalho Aguiar, 44 sala 114, Sao Paulo-SP , Brazil. whady.hueb@incor.usp.br or mass@incor.usp.br 2006 American Heart Association, Inc. Circulation is available at DOI: /CIRCULATIONAHA I-420
2 Soares et al Invasive Treatment Reduces Mortality in Diabetic Subjects I-421 published trial to date have compared medical treatment with revascularization in diabetic patients followed-up for longer periods. It is still debatable whether a strategy of early revascularization compared with a more conservative approach reduces mortality in patients with type 2 diabetes presenting with mild and stable symptoms. Therefore, in the present report, we aimed to analyze the 5-year mortality rates in patients with and without diabetes according to 3 therapeutic options, medical, surgical, and angioplasty in the MASS II population. Methods Study Design and Patient Population The study design of MASS II has been previously published elsewhere. 8 Briefly, the MASS II is a randomized, prospective, single-center study that compared 3 therapeutic strategies, medical, surgery, and angioplasty in patients with multivessel and stable coronary artery disease. A total of 611 patients were randomized between May 1995 and March The present report is a post-hoc analysis using the overall MASS II population, which was retrospectively divided into 2 groups according to the presence of diabetes at baseline. Baseline, procedural, and follow-up data were stored in a dedicated electronic database specifically built for the MASS II study. Diabetes was defined as the presence of serum glucose concentration 140 mg/dl on at least 2 separate occasions. We also considered as diabetic subjects patients with previous diagnosis using specific medication, oral drugs, or insulin. These criteria were the most accepted definition for diabetes at the beginning of the study and were maintained in the present report. 9 From the total population, 190 patients were diabetic subjects (75 in medical, 56 in angioplasty, and 59 in surgical groups) and 421 patients were nondiabetic subjects (128 in medical, 149 in angioplasty, and 144 in surgical groups). This protocol was approved by the hospital ethics committee and is in accordance with the Declaration of Helsinki. Written, informed consent was obtained from every patient. Treatment Protocol Device choice was left at the discretion of the operator and included stents, excimer laser, directional atherectomy, rotablator, and balloon angioplasty. The interventional cardiologist was encouraged to treat all arteries that were likely to contribute to ischemia and/or had lesion with 70% diameter stenosis. Angioplasty was performed according to a standard protocol that included administration of aspirin before the procedure. Dilatation of a stenotic vessel was considered successful if the residual stenosis of the lumen diameter was 50%. Patients treated with coronary stents were maintained on ticlopidine 250 mg twice daily for 1 month in addition to lifelong aspirin. For patients assigned to the surgery, the cardiac surgeon was encouraged to intervene in all feasible stenosed arteries as an attempt to accomplish complete revascularization. Use of internal mammary conduits was strongly advised for all cases. Coronary bypass was executed using standard surgical techniques, under hypothermic arrest, with the use of blood cardioplegy. The medication recommendations were not different for patients randomized to surgery, angioplasty, or medical therapy alone. All patients were treated with lifelong aspirin. Nitrates, angiotensinconverting enzyme inhibitors, and -blocking agents were administered with the objective to keep the patient free of angina. Statins were prescribed with low-fat diet with the objective to keep low-density lipoprotein cholesterol 100 mg/dl. Anti-hypertensive drugs were used according to the physician s judgment. For diabetes treatment, sulfonylurea, insulin, and metformin were used with the main objective to keep fasting glucose levels 130 mg/dl. Study Endpoints The study primary end point was to compare the impact of the 3 treatment strategies, medical, angioplasty, or surgery, in the mortality in diabetic and nondiabetic patients at 5 years. To better-evaluate the clinical outcomes, we analyzed separately the mortality trends, in 2 intervals: the first year of follow-up and for the next 4 years (years 2 to 5). The purpose of this analysis was to exclude deaths that were related to the invasive procedure, surgical or percutaneous, and to evaluate the potential protective effect of invasive strategies compared with the conservative arm in the long-term follow-up. Statistical Analysis Categorical variables were compared using Fisher exact test and continuous variables were compared using Student t test. Event rates were estimated with the Kaplan-Meier method and compared using the log-rank test. Hazard rates were calculated from the life table analyses as the death rate during a time interval, conditional on survival to the end of the preceding time interval. P 0.05 was considered to be significant. All statistical analyses were performed with the statistical package SPSS 13.0; SPSS Inc, Chicago, Ill). The authors had full access to the data and take full responsibility for their integrity. All authors have read and agree to the manuscript as written. Results Baseline and Procedural Characteristics Baseline characteristics were similar among patients randomized to medical treatment, angioplasty, or surgery within the diabetic and nondiabetic subgroups, except by a higher prevalence of previous myocardial infarction in nondiabetic subjects treated with angioplasty (compared with nondiabetic subjects in the other treatment groups) (Table 1). When pooled over treatment groups, diabetic subjects had lower prevalence of males, higher prevalence of hypertension, higher ejection fraction, and higher fasting serum glucose (Table 1). Triglycerides tended to be higher and low-density lipoprotein cholesterol tended to be lower in diabetic subjects compared with nondiabetic subjects (Table 1). The rates of revascularization of the three coronary territories at the index procedure (right coronary artery, left circumflex, and left anterior descending) were significantly lower in patients treated with angioplasty than in surgical patients, both among diabetic subjects and among nondiabetic subjects (Table 1). Overall, stents were used in 80% of patients randomized to percutaneous intervention and left internal mammary artery (IMA) or right IMA grafts were used in 95% of surgical patients (Table 1). Clinical Outcomes Patients were followed-up for an average period of days (median, 1840 days). The Figure shows the 5-year mortality curves for patients randomized to medical treatment, angioplasty, or surgery in the diabetic (Figure, A) and in the nondiabetic (Figure, B) subpopulations. The cumulative 5-year mortality was not significantly different among treatment groups within diabetic subjects (P 0.25 by log-rank) and within nondiabetic subjects (P 0.63 by log rank) (Figure). To better-evaluate the clinical outcomes along the study, the mortality trends were separately analyzed for the first year of follow-up and for the next 4 years thereafter (years 2 to 5). Both time intervals had their respective hazard rates calcu-
3 I-422 Circulation July 4, 2006 TABLE 1. Baseline Characteristics of Diabetic and Nondiabetic Subjects Randomized to Medical Treatment, Percutaneous Coronary Intervention, or Coronary Bypass Surgery Diabetic Subjects Nondiabetic Subjects Medical (n 75) PCI (n 56) CABG (n 59) Medical (n 128) PCI (n 149) CABG (n 144) P* Age, years Male sex Hypertension Insulin-dependent Previous MI Total cholesterol, mg/dl HDL-C LDL-C Triglycerides, mg/dl Serum glucose, mg/dl LVEF, % Vessel disease Treated territory Right coronary artery Left circumflex Left anterior descending N of lesions dilated Patients with stents implanted Lesions with stents implanted N of distal anastomosis LIMA and/or RIMA graft Time between randomization and treatment, days CABG indicates coronary artery bypass graft surgery; HDL-C, high-density lipoprotein cholesterol; LDL-C, low density-lipoprotein cholesterol; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention. Values are percentages or mean SD. *Diabetic vs nondiabetic subjects (pooled over treatment groups). P 0.05 among treatment groups in nondiabetic subjects. P 0.05 among treatment groups in diabetic subjects. lated, which is an estimate of the probability of death conditional on surviving to the start of the interval (Table 2). During the first year, the mortality was not statistically different among the treatment groups, both for nondiabetic subjects and for diabetic subjects (P 0.2 and P 0.5 by log-rank, respectively). Similarly, during the second period of the follow-up (years 2 to 5), the mortality of the 3 treatment groups was not different for nondiabetic subjects, when analyzing patients who have survived the first year of follow-up (P 0.5 by log rank). Conversely, among diabetic subjects, patients randomized to medical treatment (who had survived the first year) had a significant increase in mortality between years 2 and 5 (P 0.039), compared with patients treated with percutaneous intervention or surgery (with no difference in mortality between 2 and 5 years for angioplasty versus surgery; P 0.7). Cardiovascular medication usage at 5 years is shown in Table 3. Overall, diabetic subjects and nondiabetic subjects had similar prescription, except by a higher aspirin use among diabetic subjects. In total, 74% of patients were using statins at 5 years. Anti-ischemic drugs were significantly more frequent for patients randomized to medical treatment. Discussion The main findings of the present study are that the initial therapeutic approach, medical treatment, angioplasty, or surgery, did not modify the mortality trend during 5 years for nondiabetic subjects with stable multivessel coronary disease. Also, the treatment modality did not influence the outcomes during the first year in diabetic subjects. However, from the first year and afterward, diabetic subjects undergoing treatment with invasive strategies (angioplasty or surgery) had significantly improved mortality rates in comparison with patients randomized to a more conservative medical strategy. In the BARI study, diabetic subjects with multivessel coronary disease treated with balloon angioplasty had worse long-term survival than those undergoing surgery. There was no difference in long-term survival in the nondiabetic patients. 5 Interestingly, the long-term benefit of bypass surgery for diabetic subjects could be explained by the increased rates of complete revascularization in the surgical arm. 6 Based on these findings, it is reasonable to expect that patients with diabetes and multivessel disease treated with either angioplasty or surgery would have similar outcomes if both strategies could be performed with a comparable complete-
4 Soares et al Invasive Treatment Reduces Mortality in Diabetic Subjects I-423 Kaplan-Meier mortality curves for diabetic subjects (A) and nondiabetic subjects (B) randomized to medical treatment, percutaneous intervention, or surgery. Note that patients with diabetes allocated to medical management presented an increase in the risk of death after 1 year, which was maintained throughout the follow-up period thereafter. ness of revascularization. Accordingly, more recent randomized trials with coronary stenting (when more aggressive and effective percutaneous approaches were used in comparison with early trials with balloon angioplasty) did not show a major difference in mortality between angioplasty and surgery for diabetic subjects with multivessel disease. 7 Conversely, a large observational study have shown a survival benefit for patients treated with surgery, compared with angioplasty, for multivessel disease. 10 Our findings strongly support the concept that the level of revascularization is inversely proportional to the risk of death during the followup, because diabetic subjects maintained on medical treatment presented a worse prognosis than patients treated invasively. It is interesting to observe that the impact of revascularization procedures for diabetic subjects was only evident after the first year of follow-up. It could be hypothesized that, during the first year, the protective effect of invasive treatment was overcome by the incidence of procedure-related deaths. After the first year, however, the benefit of revascularization for diabetic subjects was translated into a significant reduction in mortality as compared with patients randomized to a noninvasive treatment. Curiously, the beneficial effect of revascularization on diabetic subjects occurred in a population with a significant higher proportion of females, when compared with nondiabetic subjects, a factor that has been previously reported to increase the risk of long-term complications. 11 Modern medical therapy is superior to that used in early studies, not only for coronary artery disease but also for diabetes mellitus. In MASS II, aspirin was prescribed for 90% of the patients, beta-blockers for 70%, and statins for 70%. It is important to notice that a suboptimum medication scheme did not seem explain the worse outcome observed for diabetic subjects allocated to medical treatment, which reinforces the beneficial effect of an invasive strategy for this population even in the context of optimized drug therapy. Nevertheless, the treatment of diabetes has markedly changed in the past years, with 2 different approaches (or their association) currently being undergoing intense investigation; the use of insulin or drugs that promote the increase of insulin secretion (insulin-providing approach) or the use of drugs that reduce insulin resistance (insulin-sensitizing approach). 6 Many unanswered questions about the impact of the treatment of diabetes for patients with stable coronary artery disease will probably be answered by the ongoing BARI 2D trial. 12 The present study has several limitations. It is a retrospective analysis of MASS II trial, which was not specifically designed to compare the effects of the 3 strategies in the diabetic population. Moreover, it was not powered to detect TABLE 2. Hazard Rate for Mortality for Diabetic and Nondiabetic Subjects Randomized to Medical Treatment, Percutaneous Intervention, or Coronary Bypass Surgery Year 1 Years 2 to 5 No. of Events Hazard Rate P No. of Events Hazard Rate Average Annualized Hazard Rate P Diabetic subjects Medical (75) PCI (56) CABG (59) Nondiabetic subjects 0.2 Medical (128) PCI (149) CABG (144) Hazard rate is an estimate of the probability of death during the time interval, conditional on surviving to the start of the interval.
5 I-424 Circulation July 4, 2006 TABLE 3. Medication Use at 5-Year Follow-up for Diabetic and Nondiabetic Subjects Randomized to Medical Treatment, Percutaneous Intervention, or Coronary Bypass Surgery Diabetic Subjects Nondiabetic Subjects Medical (n 56) PCI (n 47) CABG (n 50) Medical (n 112) PCI (n 130) CABG (n 121) P* Beta-blocker, % Ca channel blocker, % Aspirin, % Nitrate, % ACE inhibitor, % Statin, % Sample size reflects patients who were alive at 5 years of follow-up. ACE indicates angiotensin-converting enzyme. *Diabetic vs nondiabetic subjects (pooled over treatment groups). P 0.05 among treatment groups in diabetic subjects. P 0.05 among treatment groups in nondiabetic subjects. subtle differences in mortality, especially when considering the relatively low risk of the included patients, who had normal left ventricular function and triple vessel disease in only 50% of the cases. Also, the low number of insulindependent diabetic subjects in the study arms precluded a more detailed analysis on the outcomes of these subgroups. It should be noted that the population included in the present study was possibly at a higher risk for complications than a population selected according to a diagnostic criteria using lower levels of fasting glucose. Nevertheless, a clear reduction in the risk of death could be seen after the first year in diabetic subjects treated invasively. New therapeutic approaches for diabetes, as well as a change toward more rigid diagnostic criteria of the disease have been advocated in the past few years. Future studies should investigate whether the present findings will be reproduced in the context of the new diagnostic definitions of diabetes and more modern treatment schemes. Conclusions Surgery, angioplasty, and medical treatment did not influence the risk of death for nondiabetic subjects. For diabetic subjects, however, coronary revascularization (percutaneous or surgical) was associated with a protective effect compared with medical treatment alone, significantly decreasing the risk of death after the first year and up to 5 years. None. Disclosures References 1. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1996;94: Halon DA, Merdler A, Flugelman MY, Rennert HS, Weisz G, Shahla J, Lewis BS. Late-onset heart failure as a mechanism for adverse long-term outcome in diabetic patients undergoing revascularization (a 13-year report from the Lady Davis Carmel Medical Center Registry). Am J Cardiol. 2000;85: Weintraub WS, Stein B, Kosinski A, Douglas JS Jr, Ghazzal ZM, Jones EL, Morris DC, Guyton RA, Craver JM, King SB III. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol. 1998;31: Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reves JG, Smith PK, Anderson RD, Jones RH, Mark DB, Califf RM. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation. 1997;96: Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol. 2000;35: Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. Jama. 2005;293: Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG, Sousa JE, van Hout B, Hugenholtz PG, Unger F, Serruys PW; Arterial Revascularization Therapy Study Group. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation. 2001;104: Hueb W, Soares PR, Gersh BJ, Cesar LA, Luz PL, Puig LB, Martinez EM, Oliveira SA, Ramires JA. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol. 2004;43: American Diabetes Association. Clinical practice recommendations Diabetes Care. 1997;20(Suppl 1):S1 S Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP, Rose EA. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med. 2005;352: Jacobs AK. Coronary revascularization in women in 2003: sex revisited. Circulation. 2003;107: Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation. 2003;107: (Erratum in: Circulation. 2003;108:500.)
Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationControversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationCoronary Revascularization in Diabetic Patients
Coronary Revascularization in Diabetic Patients A Comparison of the Randomized and Observational Components of the Bypass Angioplasty Revascularization Investigation (BARI) Katherine M. Detre, MD; Ping
More informationOutcome of Coronary Bypass Surgery Versus Coronary Angioplasty in Diabetic Patients With Multivessel Coronary Artery Disease
10 CLINICAL STUDIES JACC Vol. 31, No. 1 INTERVENTIONAL CARDIOLOGY Outcome of Coronary Bypass Surgery Versus Coronary Angioplasty in Diabetic Patients With Multivessel Coronary Artery Disease WILLIAM S.
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationdoi: /CIRCULATIONAHA
Five-Year Follow-Up of the Medicine, Angioplasty, or Surgery Study (MASS II): A Randomized Controlled Clinical Trial of 3 Therapeutic Strategies for Multivessel Coronary Artery Disease Whady Hueb, Neuza
More informationCoronary Plaque Sealing: The DEFER Study and more...
Coronary Plaque Sealing: The DEFER Study and more... How Waiting Can Be Beneficial in Stable Coronary Artery Disease Patients ESC, Stockholm, 2005 M. Romanens, 21.09.2005 at www.kardiolab.ch DEFER Study:
More informationJMSCR Vol 07 Issue 01 Page January 2018
www.jmscr.igmpublication.org Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i1.109 Short Term Outcome in a Severe Coronary Artery Disease with
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationCase Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?
Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized
More informationCoronary atherosclerotic heart disease remains the number
Twenty-Year Survival After Coronary Artery Surgery An Institutional Perspective From Emory University William S. Weintraub, MD; Stephen D. Clements, Jr, MD; L. Van-Thomas Crisco, MD; Robert A. Guyton,
More informationBy 2000, more than percutaneous and
Review: Current Perspective Indications for Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in Chronic Stable Angina Review of the Evidence and Methodological Considerations Charanjit
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationTreatment Options for Angina
Treatment Options for Angina Interventional Cardiology Perspective Michael A. Robertson, M.D. 10/30/10 Prevalence of CAD in USA 15 million Americans with CAD 2 million diagnostic catheterizations 1 million
More informationDESs in Multivessel Disease
DESs in Multivessel Disease Lessons learned from large registry experience. BY DANIEL W. CARLSON, MD, AND MARK A. TURCO, MD, FACC, FSCAI For patients with limitation of ordinary physical activity secondary
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationUnprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality
Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality Shun Watanabe, MD, Tatsuhiko Komiya, MD, Genichi Sakaguchi, MD, PhD, and Takeshi Shimamoto, MD, PhD Department
More informationComparison of Coronary Artery Bypass Grafting With Drug-Eluting Stent Implantation for the Treatment of Multivessel Coronary Artery Disease
Comparison of Coronary Artery Bypass Grafting With Drug-Eluting Stent Implantation for the Treatment of Multivessel Coronary Artery Disease Jeong Hoon Yang, MD, Hyeon-Cheol Gwon, MD, Soo Jin Cho, MD, Joo
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationImpact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary
More informationJournal of the American College of Cardiology Vol. 38, No. 5, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 5, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01571-6 Survival
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationAt the end of the past century, cardiovascular disease (CVD) accounted for
Surgery for Acquired Cardiovascular Disease Mercado et al One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease:
More informationMichael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Maquet, Inc.,- unpaid consultant Cordis, Inc.,- unpaid consultant Boston Scientific, Inc.,- travel expenses paid for Syntax
More informationImportance of the third arterial graft in multiple arterial grafting strategies
Research Highlight Importance of the third arterial graft in multiple arterial grafting strategies David Glineur Department of Cardiovascular Surgery, Cliniques St Luc, Bouge and the Department of Cardiovascular
More informationLack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era
Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era B. Bao 1, N. Ozasa 1, T. Morimoto 2, Y. Furukawa 3, M. Shirotani 4, H. Ogawa 5, C. Tei 6, H.
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationManagement of Stable Coronary Disease
T h e n e w e ng l a nd j o u r na l o f m e dic i n e C l i n i c a l D e c i s i o n s Interactive at www.nejm.org Management of Stable Coronary Disease This interactive feature addresses the diagnosis
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationSurgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
More informationThe Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina
The Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina Ajay J. Kirtane,, MD Columbia University Medical Center The Cardiovascular Research Foundation Conflict of Interest
More informationInfluence of Planned Six-Month Follow-Up Angiography on Late Outcome After Percutaneous Coronary Intervention A Randomized Study
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01476-0 Influence
More informationClinical Appropriateness Guidelines: Percutaneous Coronary Intervention
Clinical Appropriateness Guidelines: Percutaneous Coronary Intervention Appropriate Use Criteria Effective Date: January 2, 2018 Proprietary Date of Origin: 08/27/2015 Last revised: 08/01/2017 Last reviewed:
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationModeling and Risk Prediction in the Current Era of Interventional Cardiology
Modeling and Risk Prediction in the Current Era of Interventional Cardiology A Report From the National Heart, Lung, and Blood Institute Dynamic Registry David R. Holmes, MD; Faith Selzer, PhD; Janet M.
More informationJames M. Kirshenbaum, MD, FACC
James M. Kirshenbaum, MD, FACC Associate Professor of Medicine Harvard Medical School Co-Director, Clinical Cardiology Director, Acute Interventional Cardiology Brigham and Women s Hospital Boston, MA
More informationPercutanous revascularization of chronic total occlusion of diabetic patients at Iraqi center for heart diseases, a single center experience 2012
www.muthjm.com Muthanna Medical Journal 2015; 2(2):76-82 Percutanous revascularization of chronic total occlusion of diabetic patients at Iraqi center for heart diseases, a single center experience 2012
More informationContemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease
Contemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease A Comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the
More informationImplications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011
Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Prof. Dr. Volkmar Falk Klinik für Herz- und Gefäßchirurgie, Universitätsspital Zürich, Schweiz In 2004 headlines were
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationCOURAGE to Leave Diseased Arteries Alone
COURAGE to Leave Diseased Arteries Alone Spencer King MD MACC, FSCAI St. Joseph s s Heart and Vascular Institute Professor of Medicine Emeritus Emory Univ. Atlanta, USA Conflict: I am an Interventionalist
More informationΔημήτριος Αγγοσράς, FETCS
ΣΕΜΙΝΑΡΙΟ ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ Δημήτριος Αγγοσράς, FETCS Επίκοσρος Καθηγηηής Καρδιοτειροσργικής Ιαηρική Πανεπιζηημίοσ Αθηνών Πανεπιζηημιακό Γενικό Νοζοκομείο Αηηικόν Randomized Controlled Trials (RCTs) Why
More informationLong-Term Outcomes of Coronary-Artery Bypass Grafting versus Stent Implantation
The new england journal of medicine original article Long-Term Outcomes of Coronary-Artery Bypass Grafting versus Stent Implantation Edward L. Hannan, Ph.D., Michael J. Racz, Ph.D., Gary Walford, M.D.,
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total
More informationLong-Term Mortality of Coronary Artery Bypass Grafting and Bare-Metal Stenting
Long-Term Mortality of Coronary Artery Bypass Grafting and Bare-Metal Stenting Chuntao Wu, MD, PhD, Songyang Zhao, MS, Andrew S. Wechsler, MD, Stephen Lahey, MD, Gary Walford, MD, Alfred T. Culliford,
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationSeven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status The BARI Investigators
Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status J. Am. Coll. Cardiol. 2000;35;1122-1129 This information is current as of July 31, 2007
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationOriginal Article. Key words transluminal coronary angioplasty, coronary artery bypass grafting, coronary artery disease
Original Article Comparative Study of the Results of Coronary Artery Bypass Grafting and Angioplasty for Myocardial Revascularization in Patients with Equivalent Multivessel Disease Paulo Roberto Dutra
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More informationComparison of Long-term Efficacy of Medical Treatment versus Percutaneous Transluminal Coronary Angioplasty (PTCA) in Single-vessel Disease
Comparison of Long-term Efficacy of Medical Treatment versus Percutaneous Transluminal Coronary Angioplasty (PTCA) in Single-vessel Disease Shinichiro NISHIYAMA, M.D., Takashi IWASE, M.D., Sugao ISHIWATA,
More informationThe Bypass Angioplasty Revascularization Investigation
Influence of the Bypass Angioplasty Revascularization Investigation National Heart, Lung, and Blood Institute Diabetic Clinical Alert on Practice Patterns Results from the National Cardiovascular Network
More informationCONTEMPORARY USE OF ARTERIAL GRAFTS DURING CORONARY ARTERY BYPASS SURGERY: PARADIGM SHIFT? OR A LITTLE (MORE) TALK THAT NEEDS A LOT MORE ACTION
CONTEMPORARY USE OF ARTERIAL GRAFTS DURING CORONARY ARTERY BYPASS SURGERY: PARADIGM SHIFT? OR A LITTLE (MORE) TALK THAT NEEDS A LOT MORE ACTION JAMES L ZELLNER MD I have no financial disclosures. 1897
More informationRevascularization In HFrEF: Are We Close To The Truth. Ali Almasood
Revascularization In HFrEF: Are We Close To The Truth Ali Almasood HF epidemic 1-2% of the population have HF At least one-half have heart failure with reduced ejection fraction (HF- REF) The most common
More informationFFR Incorporating & Expanding it s use in Clinical Practice
FFR Incorporating & Expanding it s use in Clinical Practice Suleiman Kharabsheh, MD Consultant Invasive Cardiology Assistant professor, Alfaisal Univ. KFHI - KFSHRC Concept of FFR Maximum flow down a vessel
More informationDiabetes mellitus is an established risk factor for the
Influence of Diabetes on Mortality and Morbidity: Off-Pump Coronary Artery Bypass Grafting Versus Coronary Artery Bypass Grafting With Cardiopulmonary Bypass Mitchell J. Magee, MD, Todd M. Dewey, MD, Tea
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of
More informationSetting The setting was a hospital. The economic study was carried out in Australia.
Coronary artery bypass grafting (CABG) after initially successful percutaneous transluminal coronary angioplasty (PTCA): a review of 17 years experience Barakate M S, Hemli J M, Hughes C F, Bannon P G,
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationJournal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationA Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS
Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationRandomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :
More informationPractice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationThe Influence of Previous Percutaneous Coronary Intervention in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting
Original Article The Influence of Previous Percutaneous Coronary Intervention in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting Toshihiro Fukui, MD, Susumu Manabe, MD, Tomoki Shimokawa, MD,
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationSurgery Grand Rounds
Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000
More informationCoronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy
Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Takayuki Ohno, MD, Shinichi Takamoto, MD, Noboru Motomura, MD, Minoru Ono,
More informationSURGICAL MYOCARDIAL REVASCULARIZATION: ARTERIAL VS VENOUS GRAFTS, SINGLE VS MULTIPLE GRAFTS?
SURGICAL MYOCARDIAL REVASCULARIZATION: ARTERIAL VS VENOUS GRAFTS, SINGLE VS MULTIPLE GRAFTS? Luigi Martinelli Chief, Dept. of Surgery Istituto Clinico Ligure di Alta Specialità RAPALLO During 1987 2006,
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationCoronary Heart Disease. Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents
Coronary Heart Disease Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents Neil Sawhney, MD; Jeffrey W. Moses, MD; Martin B. Leon, MD; Richard E. Kuntz, MD; Jeffrey
More informationDevelopment of a risk score to identify patients with type 2 diabetes mellitus and multivessel coronary artery disease who can defer bypass surgery
Perry et al. Diagnostic and Prognostic Research (2019) 3:3 https://doi.org/10.1186/s41512-019-0048-7 Diagnostic and Prognostic Research RESEARCH Open Access Development of a risk score to identify patients
More informationImpact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease
Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,
More informationCoronary Heart Disease in Patients With Diabetes
Journal of the American College of Cardiology Vol. 49, No. 6, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.09.045
More informationDrug-eluting stents (DESs) show a lower incidence of
ADULT CARDIAC Comparison of Off-pump Coronary Artery Bypass Grafting With Percutaneous Coronary Intervention Versus Drug-Eluting Stents for Three-Vessel Coronary Artery Disease Gijong Yi, MD, Young-Nam
More informationAcute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
More informationClinical Appropriateness Guidelines: Percutaneous Coronary Intervention
Clinical Appropriateness Guidelines: Percutaneous Coronary Intervention Appropriate Use Criteria Effective Date: March 9, 2019 Proprietary Date of Origin: 08/27/2015 Last revised: 02/01/2018 Last reviewed:
More informationAngiographic Comparison of Coronary Artery Disease in Arab Women with and without Type II Diabetes mellitus
International Conference on Coronary Heart Disease in the New Millennium Diagnosis and Management Med Principles Pract 2002;11(suppl 2):63 68 DOI: 10.1159/000066411 Received: February 12, 2002 Revised:
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationCLINICAL CONSEQUENCES OF THE
CLINICAL CONSEQUENCES OF THE FAME STUDY TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands GUIDELINES ESC SEPTEMBER 2010 FFR UPGRADED TO LEVEL
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationSeven-Year Outcome in the RITA-2 Trial: Coronary Angioplasty Versus Medical Therapy
Journal of the American College of Cardiology Vol. 42, No. 7, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00951-3
More information